# Corvus Pharmaceuticals, Inc.: financial statements, quarterly

CRVS · Nasdaq · CIK 1626971 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crvs.md) · [Financials](/companies/crvs/financials.md) · [Filings](/companies/crvs/filings.md) · [Insiders](/companies/crvs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crvs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [4.0](/filings/0001558370-24-015306.md) | [4.0 d](/filings/0001104659-26-027047.md) | [4.1](/filings/0001558370-25-006966.md) | [4.1](/filings/0001558370-25-010755.md) | [5.2](/filings/0001104659-25-106259.md) | [6.0 d](/filings/0001104659-26-027047.md) | [7.5](/filings/0001104659-26-057100.md) | [7.9](/filings/0001104659-26-091975.md) | [8.5](/filings/0001104659-25-106259.md) | [9.9 d](/filings/0001104659-26-027047.md) | [11.2](/filings/0001104659-26-057100.md) | [16.0](/filings/0001104659-26-091975.md) |
| Operating income | $m | [(5.6)](/filings/0001558370-24-015306.md) | [(5.7) d](/filings/0001104659-26-027047.md) | [(6.3)](/filings/0001558370-25-006966.md) | [(5.9)](/filings/0001558370-25-010755.md) | [(7.3)](/filings/0001104659-25-106259.md) | [(8.1) d](/filings/0001104659-26-027047.md) | [(9.9)](/filings/0001104659-26-057100.md) | [(10.3)](/filings/0001104659-26-091975.md) | [(10.6)](/filings/0001104659-25-106259.md) | [(12.2) d](/filings/0001104659-26-027047.md) | [(14.9)](/filings/0001104659-26-057100.md) | [(19.3)](/filings/0001104659-26-091975.md) |
| Income tax | $m | [0.0 d](/filings/0001558370-24-015306.md) | [0.0 d](/filings/0001104659-26-027047.md) | [0.0](/filings/0001558370-24-007093.md) | [0.0 d](/filings/0001558370-24-011076.md) | [0.0 d](/filings/0001558370-24-015306.md) | [0.0 d](/filings/0001104659-26-027047.md) | [0.0](/filings/0001104659-26-057100.md) | [0.0 d](/filings/0001104659-26-091975.md) | not reported | not reported | [0.0](/filings/0001104659-26-057100.md) | [0.0 d](/filings/0001104659-26-091975.md) |
| Net income | $m | [(6.0)](/filings/0001558370-24-015306.md) | [(6.7) d](/filings/0001104659-26-027047.md) | [(5.7)](/filings/0001104659-25-106259.md) | [(4.3)](/filings/0001104659-25-106259.md) | [(40.2)](/filings/0001104659-25-106259.md) | [(12.1) d](/filings/0001104659-26-027047.md) | [15.2](/filings/0001104659-26-091975.md) | [(8.0)](/filings/0001104659-26-091975.md) | [(10.2)](/filings/0001104659-25-106259.md) | [(12.3) d](/filings/0001104659-26-027047.md) | [(13.7)](/filings/0001104659-26-091975.md) | [(18.0)](/filings/0001104659-26-091975.md) |
| Diluted EPS | $ per share | [(0.12)](/filings/0001558370-24-015306.md) | not reported | [(0.12)](/filings/0001558370-25-006966.md) | [(0.07)](/filings/0001558370-25-010755.md) | [(0.60)](/filings/0001104659-25-106259.md) | not reported | [(0.13)](/filings/0001104659-26-057100.md) | [(0.10)](/filings/0001104659-26-091975.md) | [(0.12)](/filings/0001104659-25-106259.md) | not reported | [(0.15)](/filings/0001104659-26-057100.md) | [(0.19)](/filings/0001104659-26-091975.md) |
| Basic EPS | $ per share | [(0.12)](/filings/0001558370-24-015306.md) | not reported | [(0.12)](/filings/0001558370-25-006966.md) | [(0.07)](/filings/0001558370-25-010755.md) | [(0.60)](/filings/0001104659-25-106259.md) | not reported | [0.21](/filings/0001104659-26-057100.md) | [(0.10)](/filings/0001104659-26-091975.md) | [(0.12)](/filings/0001104659-25-106259.md) | not reported | [(0.15)](/filings/0001104659-26-057100.md) | [(0.19)](/filings/0001104659-26-091975.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [20.1](/filings/0001558370-23-017981.md) | [12.6](/filings/0001558370-25-003621.md) | [7.5](/filings/0001558370-24-007093.md) | [14.8](/filings/0001558370-24-011076.md) | [4.7](/filings/0001558370-24-015306.md) | [8.7](/filings/0001104659-26-027047.md) | [5.0](/filings/0001558370-25-006966.md) | [14.7](/filings/0001558370-25-010755.md) | [2.9](/filings/0001104659-25-106259.md) | [4.6](/filings/0001104659-26-091975.md) | [40.1](/filings/0001104659-26-057100.md) | [18.9](/filings/0001104659-26-091975.md) |
| Current assets | $m | [33.1](/filings/0001558370-23-017981.md) | [28.0](/filings/0001558370-25-003621.md) | [22.9](/filings/0001558370-24-007093.md) | [48.3](/filings/0001558370-24-011076.md) | [42.9](/filings/0001558370-24-015306.md) | [54.4](/filings/0001104659-26-027047.md) | [45.5](/filings/0001558370-25-006966.md) | [75.8](/filings/0001558370-25-010755.md) | [66.9](/filings/0001104659-25-106259.md) | [58.2](/filings/0001104659-26-091975.md) | [240](/filings/0001104659-26-057100.md) | [221](/filings/0001104659-26-091975.md) |
| Total assets | $m | [51.9](/filings/0001558370-23-017981.md) | [45.6](/filings/0001558370-25-003621.md) | [40.1](/filings/0001558370-24-007093.md) | [64.6](/filings/0001558370-24-011076.md) | [58.8](/filings/0001558370-24-015306.md) | [68.9](/filings/0001104659-26-027047.md) | [59.4](/filings/0001558370-25-006966.md) | [89.5](/filings/0001558370-25-010755.md) | [80.5](/filings/0001104659-25-106259.md) | [71.1](/filings/0001104659-26-091975.md) | [253](/filings/0001104659-26-057100.md) | [239](/filings/0001104659-26-091975.md) |
| Current liabilities | $m | [7.3](/filings/0001558370-23-017981.md) | [6.9](/filings/0001558370-25-003621.md) | [6.7](/filings/0001558370-24-007093.md) | [13.3](/filings/0001558370-24-011076.md) | [46.4](/filings/0001558370-24-015306.md) | [35.4](/filings/0001104659-26-027047.md) | [9.3](/filings/0001558370-25-006966.md) | [8.5](/filings/0001558370-25-010755.md) | [8.1](/filings/0001104659-25-106259.md) | [9.4](/filings/0001104659-26-091975.md) | [12.1](/filings/0001104659-26-057100.md) | [13.7](/filings/0001104659-26-091975.md) |
| Total liabilities | $m | [7.7](/filings/0001558370-23-017981.md) | [6.9](/filings/0001558370-25-003621.md) | [6.7](/filings/0001558370-24-007093.md) | [13.3](/filings/0001558370-24-011076.md) | [46.4](/filings/0001558370-24-015306.md) | [36.3](/filings/0001104659-26-027047.md) | [10.1](/filings/0001558370-25-006966.md) | [9.2](/filings/0001558370-25-010755.md) | [8.7](/filings/0001104659-25-106259.md) | [9.9](/filings/0001104659-26-091975.md) | [12.5](/filings/0001104659-26-057100.md) | [13.9](/filings/0001104659-26-091975.md) |
| Shareholders' equity | $m | [44.3](/filings/0001558370-24-015306.md) | [38.7](/filings/0001104659-26-027047.md) | [33.4](/filings/0001104659-25-106259.md) | [51.2](/filings/0001104659-25-106259.md) | [12.4](/filings/0001104659-25-106259.md) | [32.6](/filings/0001104659-26-091975.md) | [49.3](/filings/0001104659-26-091975.md) | [80.2](/filings/0001104659-26-091975.md) | [71.8](/filings/0001104659-25-106259.md) | [61.2](/filings/0001104659-26-091975.md) | [241](/filings/0001104659-26-091975.md) | [225](/filings/0001104659-26-091975.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.4) d](/filings/0001558370-24-015306.md) | [(5.2) d](/filings/0001104659-26-027047.md) | [(5.2)](/filings/0001558370-25-006966.md) | [(5.5) d](/filings/0001558370-25-010755.md) | [(6.3) d](/filings/0001104659-25-106259.md) | [(8.5) d](/filings/0001104659-26-027047.md) | [(8.3)](/filings/0001104659-26-057100.md) | [(5.8) d](/filings/0001104659-26-091975.md) | [(9.6) d](/filings/0001104659-25-106259.md) | [(9.2) d](/filings/0001104659-26-027047.md) | [(10.4)](/filings/0001104659-26-057100.md) | [(15.4) d](/filings/0001104659-26-091975.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-015306.md) | [0.0 d](/filings/0001104659-26-027047.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001104659-26-057100.md) | [0.1 d](/filings/0001104659-26-091975.md) | [0.0 d](/filings/0001104659-25-106259.md) | [0.0 d](/filings/0001104659-26-027047.md) | [0.1](/filings/0001104659-26-057100.md) | [0.6 d](/filings/0001104659-26-091975.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [46.6](/filings/0001558370-23-017981.md) | [46.6](/filings/0001558370-24-007093.md) | [47.5](/filings/0001558370-24-011076.md) | [49.0](/filings/0001558370-24-015306.md) | [49.0](/filings/0001558370-25-006966.md) | [59.7](/filings/0001558370-25-010755.md) | [66.7](/filings/0001104659-25-106259.md) | [75.2](/filings/0001104659-26-057100.md) | [77.8](/filings/0001104659-26-091975.md) | [82.8](/filings/0001104659-25-106259.md) | [90.0](/filings/0001104659-26-057100.md) | [92.4](/filings/0001104659-26-091975.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 84,120,944 at 2026-08-06, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-091975.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.